

# Index

## A

Adrenoleukodystrophy (ALD), 84, 85  
Adrenomyeloneuropathy (AMN), 46  
ALD. *See* Adrenoleukodystrophy (ALD)  
AMN. *See* Adrenomyeloneuropathy (AMN)  
ARSA. *See* Arylsulfatase A (ARSA)  
Arylsulfatase A (ARSA), 52, 82–83

## B

Biology, lysosomal  
  autophagy, 3  
  cytotoxicity, 4  
  endocytosis and exocytosis, 3  
  endosomes, 4  
  hydrolases, 3  
  macromolecules, 2–3  
  organelle, 2  
  trans-Golgi-network (TGN), 3, 14, 15

## C

Canavan disease, 88  
Cardiovascular system, 67  
CBT. *See* Cord blood transplant (CBT)  
Central nervous system (CNS), 38  
Chaperone therapy  
  blood-brain barrier, 31  
  DNA missense mutations, 31  
  Hex A deficiency, 31  
  treatment, LSDs, 31  
Clinical aspects, LSDs  
  disorders and organelles, 4–12

  genetic defect, 4  
  heterogeneous diseases, 4  
  MPS, 4  
  neurological disease, 13  
  prognosis, 13  
  substrate availability, 4  
Clinical trials, hESC-derived cells, 96  
CNS. *See* Central nervous system (CNS)  
Concluding remarks, LSD  
  clinical management, 113  
  ERT administration, 114  
  Hurler syndrome, 113–114  
  MPSIH and mannosidosis, 114  
  outcomes, factors  
    age at diagnosis, 116–117  
    complicated therapy, 116  
    diseases, 115  
    genotype, 116  
    multi-disciplinary follow up, 116  
    reversing substrate accumulation, 117–118  
  therapeutic options, 119–120  
  “transplant refractory”, 118  
  “transplant sensitive”, 118  
Conditioning regimen, 40, 54, 55  
Cord blood transplant (CBT), 38  
Cross correction  
  cultured cells, 14  
  HSC gene therapy, 84  
  LSDs, 14  
  metabolic defects, 37  
  microencapsulation, 18  
  physiologic process, 14  
  therapeutic strategies, 14

**D**

- Disease modifying treatment
  - chronic conditions, 13
  - ERT, 16–17
  - HSCT, 14–16
  - SRT, 17

**E**

- Embryonic stem cells (ESCs)
  - cell-therapy, 95
  - clinical trials, 96
  - derivation and characteristics, 94–95
  - drawbacks, 97
  - gene correction, 96–97
  - therapeutic cloning, SCNT
    - (*see* Somatic cell nuclear transfer (SCNT))
- Enzyme replacement therapy (ERT)
  - blood-brain barrier, 64
  - cerezyme, 22
  - chaperone, 31–32
  - description, 21–22
  - genzyme, 22
  - glucocerebrosidase, 16
  - vs.* HSCT, 71–72
  - human placenta, 16
  - individual disorders
    - alpha mannosidase deficiency, 25–26
    - arylsulfatase A deficiency, 25–26
    - Fabry disease, 24
    - GD, 23–24
    - MPS, 25
    - Pompe disease, 24–25
    - sphingomyelinase deficiency, 25
  - limitations
    - Cerezyme®, 26
    - development, antibodies, 27
    - disease burden, 27
    - efficacy, therapy, 27
    - financial burden, 27
    - GD, 26
    - Myozyme®, 27
    - natural disease, 26
    - organ-specific variations, 27
  - and LSDs, 16, 17, 21
  - mannose-6-phosphate receptor, 21
  - MPS I, 41, 42
  - pharmacological quantities, 21
  - recombinant enzyme, 16
  - residual disease, 22, 23
  - SRT, 28–30
  - stop codon read through, 32
  - treatment goals, 22
  - type 1 Gaucher, 67

- ERT. *See* Enzyme replacement therapy (ERT)
- ESCs. *See* Embryonic stem cells (ESCs)

**F**

- Fabry disease
  - agalsidase, 24
  - chaperone therapy, 31
  - clinical trials, 24
  - HSCT, 24
  - X-linked disorder, 24
- Future perspectives. *See* Concluding remarks, LSD

**G**

- GAGs. *See* Glycosaminoglycans (GAGs)
- Galactocerebroside  $\beta$ -galactosidase (GALC), 51
- GALC. *See* Galactocerebroside  $\beta$ -galactosidase (GALC)
- Gaucher disease (GD)
  - autosomal recessive disorder, 23
  - Cerezyme® therapy, 23
  - ERTs, 22
  - glucosylceramide, 23
  - hepato-splenomegaly, 65
  - neurological involvement, 23
  - pathology, 29
  - sphingolipidoses, 67
  - taliglucerase alfa, 24
  - therapeutic goals, 29
  - Zavesca®, 32
- GD. *See* Gaucher disease (GD)
- Gene therapy (GT). *See also* Hematopoietic stem cell (HSC) gene therapy and LSDs, 17
  - microencapsulation technique, 17, 18
  - viral vector delivery systems, 17
- GLD. *See* Globoid cell leukodystrophy (GLD)
- Globoid cell leukodystrophy (GLD)
  - animal model, 83
  - GALC, 51
  - Krabbe disease, 51, 52
  - murine model, 85
  - neuroinflammation, 88
  - psychosine, 51
  - UCBT, 52
- Glycogen storage disease (GSD), 24
- Glycosaminoglycans (GAGs), 30, 42
- Graft *versus* host disease (GVHD), 44
- GSD. *See* Glycogen storage disease (GSD)
- GT. *See* Gene therapy (GT)
- GVHD. *See* Graft *versus* host disease (GVHD)

**H**

- HCT. *See* Hematopoietic cell transplantation (HCT)
- Hematopoietic cell transplantation (HCT)  
 and CBT, 38  
 and CNS, 38  
 cross-correction, 37  
 donor cells, 37  
 GLD, 51–52  
 Hurler syndrome, MPS IH, 40–42  
 IEM (*see* Inborn errors of metabolism (IEM))  
 metabolic correction, 37  
 miscellaneous disorders, 54  
 MLD, 52–54  
 MPS syndromes, 42–45  
 outcomes, 38  
 X-ALD (*see* X-linked adrenoleukodystrophy (X-ALD))
- Hematopoietic stem cell (HSC) gene therapy  
 approaches, 81  
 cross correction, 84  
 delivery systems, 87–88  
 development, immune responses, 87  
 enzyme levels, 82  
 issues, clinical translation, 88–89  
 microglia (*see* Microglia)  
 preclinical data, 87  
 safety, 86  
 systemic and CNS-directed gene therapy, 88  
 therapeutic efficacy and dose-effect relationship, 82–83
- Hematopoietic stem cell transplantation (HSCT)  
 biochemical defects, 14  
 bone marrow transplantations, 14  
 cardiovascular system, 67  
 clinical manifestations, 72–75  
 cross-correction, 14, 64  
 disorders *vs.* patients, 70–71  
*vs.* ERT, 71–72  
 intracellular processes, 14, 15  
 liver and spleen, 65  
 lysosomal enzyme, 63  
 microglia cells, 15  
 morbidity and mortality risks, 15  
 M6P receptors, 14, 15  
 neurodevelopmental outcome, 64  
 organ systems, variation, 70  
 pathogenesis, 63  
 physical characteristics, 69  
 respiratory system, 67  
 skeletal system, 65–67  
 variability, patients, 69  
 vision and hearing, 68–69

- Hex A. *See* Hexosaminidase A (Hex A)
- Hexosaminidase A (Hex A), 31
- HSC gene therapy. *See* Hematopoietic stem cell (HSC) gene therapy
- HSCT. *See* Hematopoietic stem cell transplantation (HSCT)
- Hunter's syndrome  
 chronic GVHD, 44  
 fibroblasts, 37  
 GAG, 42  
 HCT, 43  
 I2S deficiency, 42  
 MRI, 43  
 neurocognitive outcomes, 43, 44  
 recombinant enzyme, 42
- Hurler syndrome, MPS IH  
 clinical outcomes, 42  
 donor cell engraftment, 40  
 ERT, 41, 42  
 fibroblasts, 37  
 GAGs, 40  
 hydrocephalus, 40  
 musculoskeletal features, 41

**I**

- Iduronate-2-sulfatase (I2S), 42
- Inborn errors of metabolism (IEM)  
 donor hierarchy, 54, 55  
 hematopoietic cell transplantation (*see* Hematopoietic cell transplantation)  
 mixed-chimerism, 55–56  
 MPS, 54  
 transplant guidelines, 54
- Induced pluripotent stem cells (iPSCs)  
 reprogramming  
 advantages, fibroblasts, 100–101  
 cell therapy and safety, 104–105  
 c-myc expression, 100  
 derivation and characteristics, 99–100  
 description, 94  
 and ESC, treatment  
 cell therapy, 106–107  
 drug development, 107  
 Gaucher disease type III, 106  
 GLD and MPSVII, 105–106  
 fibroblasts (f-iPSC) and blood (bl-iPSCs), 101–102  
 human cord blood cells, 101  
 keratinocytes, 101  
 patient specific, 103–104  
 SCNT technology, 94  
 therapeutic potential, 102–103  
 Zn-fingers and TALENs, 97

iPSCs reprogramming. *See* Induced pluripotent stem cells (iPSCs) reprogramming  
 I2S. *See* Iduronate-2-sulfatase (I2S)

## K

Krabbe disease, 38, 51, 52

## L

Late infantile neuronal ceroid lipofuscinosis (LINCL), 88  
 LINCL. *See* Late infantile neuronal ceroid lipofuscinosis (LINCL)  
 Long term outcomes. *See* Hematopoietic stem cell transplantation (HSCT)  
 LSDs. *See* Lysosomal storage diseases (LSDs)  
 Lysosomal biology, 2–4  
 Lysosomal storage diseases (LSDs)  
   biology, lysosomal, 2–4  
   cardiomegalia glycogenica diffusa, 2  
   cellular organelle, 1  
   development, therapies, 13  
   disease modifying treatment, 14–17  
   drugs, 18  
   genetherapy (*see* Genetherapy)  
   glucocerebroside, 2  
   and GT, 17–18  
   impaired degradation, heparan sulfate, 44  
   metabolic diseases, 1  
   and MPS, 2  
   murine models, 18  
   non-neurological, 21  
   pathophysiology processes, 17  
   small molecules therapy, 18  
   supportive care, 13–14

## M

Magnetic resonance imaging (MRI), 43  
 Mannose-6-phosphate receptors (M6P receptors), 14, 15  
 Metachromatic leukodystrophy (MLD)  
   ARSA, 52  
   CB grafts, 53, 54  
   ERT, 53  
   HSC transplantation, 83  
   lysosomal accumulation, 52  
   NCV, 52, 53  
   outcomes, HCT, 53  
   preclinical studies, 88  
   UCB transplantation, 53

Microglia reconstitution and efficacy timing, 84–85  
 ML. *See* Mucopolipidosis (ML)  
 MLD. *See* Metachromatic leukodystrophy (MLD)  
 M6P receptors. *See* Mannose-6-phosphate receptors (M6P receptors)  
 MPS. *See* Mucopolysaccharidosis (MPS)  
 MRI. *See* Magnetic resonance imaging (MRI)  
 Mucopolipidosis (ML)  
   cardiovascular system, 67  
   characteristics, 69  
   joints and bones, 65  
   liver and spleen, 65  
   respiratory system, 68  
   vision and hearing, 68–69  
 Mucopolysaccharidosis (MPS)  
   cardiovascular manifestations, 67  
   characteristics, 69  
   clinical improvements, 32  
   description, 64  
   ERT, 25  
   GAGs, 30  
   hepato-splenomegaly, 65  
   Hunter's syndrome, 42–44  
   joints and bones  
     cord compression, 66  
     “dysostosis multiplex”, 65  
     growth plate, 65  
     Hurler syndrome, 66  
   respiratory system, 68  
   Sanfilippo syndrome, 44–45  
   type I (MPS I), 4  
   vision and hearing, 68–69

## N

NCV. *See* Nerve conduction velocity (NCV)  
 Nerve conduction velocity (NCV), 52, 53  
 Networks, 3, 4  
 Neurodevelopmental outcome, 64  
 Niemann-pick disease type C (NPC), 25–26, 29–30, 32

## O

Outcomes, LSD  
   age at diagnosis, 116–117  
   complicated therapy, 116  
   diseases, 115  
   genotype, 116  
   multi-disciplinary follow up, 116  
   reversing substrate accumulation, 117–118

**P**

Patient specific iPSC generation, 103–104

Pompe disease

cardiomyopathy, 24

GSD, 24

infantile, 22, 25, 27

Myozyme<sup>®</sup>, 24, 27

**R**

Reprogramming, iPSCs. *See* Induced pluripotent stem cells (iPSCs) reprogramming

Respiratory system, 68

**S**

Sanfilippo syndrome

autosomal recessive LSD, 44

cyclosporine, 45

GVHD, 45

neurocognitive decline, 45

sulfamidase, 44

transplant outcomes, 44

SCNT. *See* Somatic cell nuclear transfer (SCNT)

Sensory system, 68–69

Skeletal outcome

Gaucher disease, 67

Hurler syndrome, 66

ML (*see* Mucopolidosis (ML))

MPS (*see* Mucopolysaccharidosis (MPS))

Small molecule therapy

chaperone therapy, 181

ERT (*see* Enzyme replacement therapy (ERT))

MPS disease, 30

substrate reduction therapy (SRT), 18

Somatic cell nuclear transfer (SCNT)

genetic correction, 97

ICM isolation, 97, 98

immune-deficient Rag2(-/-) mice, 97–98

iPSC technology, 94

limitations, human application, 99

nuclear transfer (nt) ESCs, 98–99

SOT. *See* Substrate optimization therapy (SOT)

SRT. *See* Substrate reduction therapy (SRT)

Stop codon read through, 32

Substrate optimization therapy (SOT), 30

Substrate reduction therapy (SRT)

adverse effects, Zavesca<sup>®</sup>, 28

disorders, 30

GD, 29

genistein, 30

and LSDs, 17

NPC, 29–30

small molecule therapy, 18

SOT, 30

therapy, LSDs, 28

Supportive care

somatic care, 14

standard care, 13

surgical interventions, 13

**T**

Tale like-effector nucleases (TALENs), 97, 106

TALENs. *See* Tale like-effector nucleases (TALENs)

**U**

UCBT. *See* Unrelated cord blood transplantation (UCBT)

Unrelated cord blood transplantation (UCBT), 52

**V**

Very long chain fatty acids (VLCFA), 46

VLCFA. *See* Very long chain fatty acids (VLCFA)

**X**

X-linked adrenoleukodystrophy (X-ALD)

adrenal insufficiency, 46

AMN, 46

cellular therapy, 50

cerebral, 46–48

clinical management, 47–48

diagnostic, 46

extensive changes, 47

MRI, 47

stem cell transplantation

adrenal dysfunction, 50

AMN, 49

cerebral, 49

donors, 49

HCT, 48–50

MRI, 49

VLCFA, 46